Screener
Agios Pharmaceuticals AGIO Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 92%+3.8pp | 90%+2.5pp | 88.3%-0.3pp | 87.2%-2.2pp | 88.2%-1.1pp | |
| Operating margin | -466.8%+662pp | -720%+469pp | -873.9%+293pp | -1,061.8%+176pp | -1,129.1%+165pp | |
| Net margin | -418.2%— | -639.8%— | -764%— | —— | —— | |
| Returns | ||||||
| Return on equity | -34.3%— | -32.8%— | -30.2%— | —— | —— | |
| Return on invested capital | -40%+6.7pp | -38.5%+2.8pp | -35.4%+1.3pp | -35.6%-0.7pp | -46.7%+4.0pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 10.2×-4.3× | 14.2×-4.3× | 11.5×-0.4× | 13.8×+4.8× | 14.5×+4.4× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×-0.1× | |
| Per Share | ||||||
| Book value per share | $17.25-27.0% | $18.87-26.1% | $20.58-22.7% | $22.09-20.6% | $23.64+103% | |
| Valuation | ||||||
| Market capitalization | $1.91B-13.0% | $1.98B+18.1% | $1.59B-15.3% | $2.33B-7.7% | $1.94B-20.9% | |
| Price / sales | 19.4×-34.2× | 30×-15.3× | 29.4×-22.0× | 52.1×-24.8× | 47.4×-30.8× | |
| Price / book | 1.9×+0.3× | 1.8×+0.6× | 1.3×+0.1× | 1.8×+0.3× | 1.4×-2.3× |
FAQ
- What are Agios Pharmaceuticals's profit margins?
- Agios Pharmaceuticals (AGIO) runs a 92.0% gross margin and a -466.8% operating margin, with a -418.2% net margin.
- Where do Agios Pharmaceuticals's ratios come from?
- Every ratio is computed from Agios Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
